Choose One, Not Both: Why Balanced Biopharma Funds Stumble
This article was originally published in Start Up
By the end of this year, three major US venture firms---JP Morgan Partners, the American affiliate of Apax, and MPM Capital--will be transformed. Their partners are leaving; their strategies are changing. And their stories are all marked by their common failure to combine early-stage biopharmaceutical venture capital with later-stay growth capital and buyouts into so-called "balanced funds."
You may also be interested in...
Clarus Ventures, a year-and-a-half removed from raising its debut fund, likely will return for seconds later this year, and the firm is betting its new strategy for investing in medical device companies promises to produce returns that its limited partners will enjoy.
Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.
Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.